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A 45-year-old patient with IgG myeloma was found to be
refractory to five cycles of continuous infusion cyclopho-
sphamide, vincristine, doxorubicin and dexamethasone.
Approximately 50% reduction in paraprotein was achieved
with 6 months of thalidomide and dexamethasone. An
autograft was planned, but in view of the young age and
poor response to initial chemotherapy, human leukocyte
antigen (HLA) typing was performed for a possible mini-
allograft in the event of a poor response to the autograft. A
brother was found to be HLA-identical. Autologous stem
cells were mobilized with 5 days of granulocyte-colony
stimulating factor (G-CSF) (10mg/kg in two divided doses
per day). The total number of cells collected over 2 days
of apheresis was 2.56 108 mononuclear cells/kg with a
CD34þ cell dose of 5 106/kg.
Melphalan was administered at the dose of 200mg/m2
and unmanipulated stem cells were infused the next day. G-
CSF was started on day þ 7. Neutropenic fever was treated
with meropenem, teicoplanin and amphotericin B. He
continued to remain pancytopenic on day þ 18. Bone
marrow on day þ 19 revealed marked hypocellularity with
no evidence of myeloma. New parenchymal lung infiltrates
developed consistent with a breakthrough fungal infection
on a chest computerized tomography scan. As there was no
evidence of engraftment by day þ 21, it was decided to
proceed with a mini-allograft from the HLA-identical
sibling.
He was conditioned with a combination of fludarabine
90mg/m2 over 3 days (days 4 to 2) and a single dose of
200 cGy total body irradiation on day 0. The donor was
mobilized with G-CSF and 19.3 106 CD34þ cells/kg
collected and infused. Cyclosporine and mycophenolate
were used as graft-versus-host disease (GVHD) prophy-
laxis. Antimicrobial therapy was continued and G-CSF was
started on day þ 5 to hasten engraftment. Granulocyte
transfusions were given on days þ 2 and þ 5. Prompt
engraftment was achieved with an absolute neutrophil
count of 4500/mm3 on day þ 8 and an unsupported
platelet count of 420 000/mm3 by day þ 9. Chimerism
analysis using variable number tandem repeats performed
on day þ 30 showed complete donor-type engraftment. He
developed grade II acute GVHD involving the gastro-
intestinal tract, which responded to treatment with steroids.
On day þ 51, cytomegalovirus (CMV) disease was
diagnosed on biopsy and blood polymerase chain reaction
(PCR) when diarrhea and vomiting developed. This was
initially treated with ganciclovir, but therapy was switched
to leflunomide (100mg daily for 3 days, followed by
20mg once daily) when ganciclovir-induced pancytopenia
developed. On a total of 4 weeks of leflunomide, there was
gradual improvement in CMV disease with complete
resolution of symptoms and a negative blood PCR. At
the last follow-up 16 months after the allograft, he has
limited chronic GVHD on cyclosporine and alternate-day
corticosteroids. The performance status is normal with no
evidence of fungal or CMV infection. Serum immunofixa-
tion is negative and there is 100% donor-type chimerism.
Primary engraftment failure following an autologous
transplant is very uncommon but has serious conse-
quences.1–4 Prolonged neutropenia in the setting of graft
failure increases the risk of fungal infections that usually
respond poorly to therapy because of persistently low
counts. Second transplants following graft failure or
relapse are generally associated with a poor outcome
related mainly to infection and organ toxicity5, but
improved outcome has been reported with the use of
reduced-intensity allografts because of lower toxicity.6,7,8
Our patient had active fungal infection at the time of the
allogeneic transplant, but a combination of antifungal
therapy along with granulocyte transfusions and prompt
donor engraftment helped in controlling and subsequently
curing the fungal infection. The use of leflunomide to treat
CMV was based on data from the renal transplant group at
our centre9 and case reports on its use in allograft
recipients.10
We conclude that a mini-allograft may be a reasonable
treatment option in selected patients with failure of
autologous engraftment.
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